Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.05
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.38 +3.03%
Revenue Growth %: -49.8%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
UBAB, LOAN, FITB, More
Revenue Growth %: -49.8%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
UBAB, LOAN, FITB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.05), versus ($0.07) reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
- South Plains Financial Inc. (SPFI) Tops Q2 EPS by 1c
- Freedom Broker Upgrades Morgan Stanley (MS) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
